KZR Kezar Life Sciences Inc.

2.95
+0.06  (+2%)
Previous Close 2.89
Open 2.89
Price To Book 0.65
Market Cap 56,467,853
Shares 19,141,645
Volume 120,386
Short Ratio
Av. Daily Volume 99,373
Stock charts supplied by TradingView

NewsSee all news

  1. Kezar Life Sciences to Host Conference Call and Webcast during the American College of Rheumatology Annual Meeting to Discuss Updated Results with KZR-616

    SOUTH SAN FRANCISCO, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet

  2. Kezar Life Sciences Reports Third Quarter 2019 Financial Results and Provides Business Update

    Additional data from the ongoing Phase 1b portion of the MISSION study to be presented at the 2019 ACR/ARP Meeting in Atlanta, GAPhase 2 MISSION, PRESIDIO, and MARINA trials with KZR-616 are progressingKZR-261 nominated

  3. Kezar Life Sciences Announces Presentations of Four Abstracts at the 2019 ACR/ARP Annual Meeting

    SOUTH SAN FRANCISCO, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet

  4. Kezar Life Sciences to Present at the 2019 Cantor Global Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet

  5. Kezar Life Sciences Announces Presentations at Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1b updated data to be presented at ACR/ARP November 12, 2019. Phase 2 interim analysis 1H 2021 with final data 2H 2021.
KZR-616
Lupus
Phase 1 initiation announced March 6, 2019.
KZR-616
Healthy volunteers
Phase 2 interim analysis 4Q 2020 with final data due mid-2021.
KZR-616
Autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP)
Phase 2 data due 2H 2021.
KZR-616
Dermatomyositis and polymyositis

Latest News

  1. Kezar Life Sciences to Host Conference Call and Webcast during the American College of Rheumatology Annual Meeting to Discuss Updated Results with KZR-616

    SOUTH SAN FRANCISCO, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet

  2. Kezar Life Sciences Reports Third Quarter 2019 Financial Results and Provides Business Update

    Additional data from the ongoing Phase 1b portion of the MISSION study to be presented at the 2019 ACR/ARP Meeting in Atlanta, GAPhase 2 MISSION, PRESIDIO, and MARINA trials with KZR-616 are progressingKZR-261 nominated

  3. Kezar Life Sciences Announces Presentations of Four Abstracts at the 2019 ACR/ARP Annual Meeting

    SOUTH SAN FRANCISCO, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet

  4. Kezar Life Sciences to Present at the 2019 Cantor Global Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet

  5. Kezar Life Sciences Announces Presentations at Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet